NASDAQ: IOBTIo Biotech Inc Stock
$0.90-0.01 (-1.1%)
Updated Oct 28, 2025
IOBT Price
$0.90
Fair Value Price
$0.88
Market Cap
$59.36M
52 Week Low
$0.32
52 Week High
$2.79
P/E
-0.57x
P/B
37.29x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$103.99M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
25.59
Operating Cash Flow
-$83M
Beta
0.88
Next Earnings
Nov 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
IOBT Overview
IO Biotech Incorporated is a biopharma company developing immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103 is in clinical trials to treat melanoma, as well as lung, bladder, and head and neck cancers. IO Biotech was incorporated in 2014 and is headquartered in Copenhagen, Denmark.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IOBT's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IOBT
Ranked#475 of 487
Ranked#475 of 487
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.10 | A | |
| $12.63 | A | |
| $7.24 | A |
Be the first to know about important IOBT news, forecast changes, insider trades & much more!
IOBT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IOBT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IOBT ($0.90) is overvalued by 2.14% relative to our estimate of its Fair Value price of $0.88 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IOBT ($0.90) is not significantly undervalued (2.14%) relative to our estimate of its Fair Value price of $0.88 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IOBT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IOBT due diligence checks available for Premium users.
Valuation
IOBT fair value
Fair Value of IOBT stock based on Discounted Cash Flow (DCF)
Price
$0.90
Fair Value
$0.88
Overvalued by
2.02%
IOBT ($0.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IOBT ($0.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IOBT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IOBT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.57x
Industry
-89.89x
Market
40.54x
IOBT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
37.29x
Industry
4.99x
IOBT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IOBT's financial health
Profit margin
Revenue
$0.0
Net Income
-$26.2M
Profit Margin
0%
IOBT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$42.3M
Liabilities
$40.7M
Debt to equity
25.59
IOBT's short-term assets ($38.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IOBT's short-term assets ($38.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IOBT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.8M
Investing
-$26.0k
Financing
$11.5M
IOBT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IOBT vs Biotech Stocks
Io Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.